Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Non-Current Debt (2016 - 2023)

Historic Non-Current Debt for Avalo Therapeutics (AVTX) over the last 8 years, with Q1 2023 value amounting to $10.5 million.

  • Avalo Therapeutics' Non-Current Debt changed N/A to $10.5 million in Q1 2023 from the same period last year, while for Mar 2023 it was $10.5 million, marking a year-over-year change of. This contributed to the annual value of $13.5 million for FY2022, which is 5892.55% down from last year.
  • Avalo Therapeutics' Non-Current Debt amounted to $10.5 million in Q1 2023.
  • Avalo Therapeutics' Non-Current Debt's 5-year high stood at $32.8 million during Q4 2021, with a 5-year trough of $10.5 million in Q1 2023.
  • For the 4-year period, Avalo Therapeutics' Non-Current Debt averaged around $16.9 million, with its median value being $14.3 million (2019).
  • Its Non-Current Debt has fluctuated over the past 5 years, first tumbled by 67.73% in 2019, then plummeted by 5892.55% in 2022.
  • Over the past 4 years, Avalo Therapeutics' Non-Current Debt (Quarter) stood at $14.3 million in 2019, then skyrocketed by 130.33% to $32.8 million in 2021, then plummeted by 58.93% to $13.5 million in 2022, then decreased by 22.36% to $10.5 million in 2023.
  • Its Non-Current Debt stands at $10.5 million for Q1 2023, versus $13.5 million for Q4 2022 and $16.5 million for Q3 2022.